Taiho Oncology, Inc.

This early-stage study tested an experimental drug called TAS3351 in 18 people with advanced non-small cell lung cancer that had a specific genetic change (EGFR C797S mutation). The goal was to see if the drug was safe and could shrink tumors. The study was stopped early, so resu…

This study tested a combination of two drugs—futibatinib and pembrolizumab—in people with advanced or spreading bladder cancer who couldn't receive standard chemotherapy. The goal was to see if the combo could shrink tumors and be safe. The trial was stopped early after enrolling…

This study tested a drug called futibatinib in 115 people with advanced cancers (solid tumors or blood cancers) that have specific FGFR gene changes. The goal was to see if the drug could shrink tumors or eliminate signs of cancer. The trial was stopped early, so results are limi…

This early-stage study tested a new drug called TAS2940 in 29 people with advanced solid tumors (like lung, breast, or brain cancer) that had certain genetic changes (EGFR or HER2). The goal was to find a safe dose and see if it could shrink tumors. The trial was stopped early, s…

This study tested a drug called TAS-120 (futibatinib) in people with advanced breast cancer that has a specific genetic change (FGFR amplification). The drug was given alone or with hormone therapy (fulvestrant). The trial aimed to see if tumors shrank or stopped growing. However…